Nonprescription Drugs Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Eric Brass, MD/PhD, Harbor-UCLA Medical Center, to acting chair and heir apparent upon expiration of four-year term of former chair Ralph D'Agostino, PhD, Boston University on May 31. D'Agostino continues to participate in the committee as consultant who may vote on issues on a meeting-by-meeting basis. If Brass is to become chairman, his nomination will likely be approved in about two months, along with nominations to replace three other committee vacancies left by Cage Johnson, MD, University of Southern California, Beth Slingluff, Carondelet St. Mary's Hospital (Tucson, Ariz.) and Theodore Tong, University of Arizona College of Pharmacy...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: